Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJulie R. Brahmer, John A. Thompson, Natasha B. Leighl et al.|Journal of Clinical Oncology|2018Cited by 3.7k
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJohn A. Thompson, Jillian L. Scavone, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020John A. Thompson, Anita M. Engh, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2020Cited by 484
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in OncologyJohn A. Thompson, Lisa Hang, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 416
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityYared Hailemichael, Adi Diab, Daniel H. Johnson et al.|Cancer Cell|2022Cited by 338